Abstract Aims The Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients
(ELDERCARE-AF) trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was …

Aims Elderly atrial fibrillation (AF) patients with risk factors of bleeding are often considered
ineligible for standard oral anticoagulants (OACs). The Edoxaban Low-Dose for EldeR …

Background The risks of thromboembolic and hemorrhagic events in patients with atrial
fibrillation both increase with age; therefore, net clinical benefit analyses of anticoagulant …

Elderly and frail patients with atrial fibrillation (AF) are at increased risk of thrombotic events,
bleeding, and death compared to their counterparts, making their management challenging …

Balancing stroke prevention and risk of bleeding in patients with atrial fibrillation (AF) is
challenging. Direct oral anticoagulants (DOACs) are by now considered standard of care for …

Edoxaban—a non–vitamin K antagonist oral anticoagulant (NOAC)—60-mg and 30-mg
once-daily dose regimens are noninferior versus well-managed warfarin for the prevention …

Aims The aim of the present meta-analysis was to evaluate the efficacy and safety of non-
vitamin K oral antagonists (NOACs) vs. vitamin K antagonists (VKAs) in elderly patients with …

Background: Elderly population is known to be associated with polymedication,
comorbidities and altered drug pharmacokinetics. However, the most adequate oral …

Background: Elderly patients with atrial fibrillation (AF) treated with anticoagulants are at
higher risk of both ischemic and bleeding events compared to younger patients. Intracranial …

Background We investigated the predictors related to major bleeding events during
treatment with edoxaban 15 mg in patients aged≥ 80 years with nonvalvular atrial …